We have located links that may give you full text access.
Nucleotide-binding oligomerization domain (NOD) plays an important role in neonatal infection.
International Journal of Biological Macromolecules 2019 January
OBJECTIVE: To explore the expression and function of nucleotide-binding oligomerization domain (NOD) proteins NOD1 and NOD2 and provide guidance for prophylaxis and treatment of neonatal infection.
METHODS: Peripheral blood samples were collected from preterm infants, term infants and, healthy adult volunteers. A portion of collected blood was used to examine the expression of NOD1 and NOD2 by real-time PCR. The remaining blood was stimulated in vitro with NOD2 agonist L-Ala-D-Glu-meso (Tri-DAP) or NOD1 agonist muramyl dipeptide (MurNAc-L-Ala-D-isoGln; MDP) for 4 h. Consequently, the levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) were quantified by enzyme-linked immunosorbent assay (ELISA).
RESULTS: NOD1 expression was found to be decreased in preterm and term newborns compared with adults. NOD2 was significantly lower in preterm infants alone in comparison with adults. After treated by Tri-DAP or MDP, the levels of IL-6 and TNF-α in peripheral blood were significantly lower in preterm and term newborns when comparing to adults.
CONCLUSION: NOD1 and NOD2 expression and induced release of pro-inflammatory mediators were impaired in infants, contributing to the high susceptibility of infants to infection. Our results insisted on developing a new immunological approach for prophylaxis and treatment of neonatal infection.
METHODS: Peripheral blood samples were collected from preterm infants, term infants and, healthy adult volunteers. A portion of collected blood was used to examine the expression of NOD1 and NOD2 by real-time PCR. The remaining blood was stimulated in vitro with NOD2 agonist L-Ala-D-Glu-meso (Tri-DAP) or NOD1 agonist muramyl dipeptide (MurNAc-L-Ala-D-isoGln; MDP) for 4 h. Consequently, the levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) were quantified by enzyme-linked immunosorbent assay (ELISA).
RESULTS: NOD1 expression was found to be decreased in preterm and term newborns compared with adults. NOD2 was significantly lower in preterm infants alone in comparison with adults. After treated by Tri-DAP or MDP, the levels of IL-6 and TNF-α in peripheral blood were significantly lower in preterm and term newborns when comparing to adults.
CONCLUSION: NOD1 and NOD2 expression and induced release of pro-inflammatory mediators were impaired in infants, contributing to the high susceptibility of infants to infection. Our results insisted on developing a new immunological approach for prophylaxis and treatment of neonatal infection.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app